New Insights Into the Long-term Benefits of Deuruxolitinib in AA
The Dermatology Digest
NOVEMBER 3, 2024
Alopecia areata patients continue to improve out to 1.5 years with 8mg deuruxolitinib (Leqselvi, Sun Pharma), according to new data presented at the 2024 Fall Clinical Dermatology Conference in Las Vegas, NV. TDD Editorial Advisory Board Member Brett King, MD, PhD, an Associate Professor of Dermatology at Yale University School of Medicine in New Haven, CT, explains why this long-term data is so important for patients and providers.
73 
Let's personalize your content